Figures & data
Figure 1. Flow diagram of the trial. *Other reasons included that the subject went out (2 subjects at Day 1, both in the Zagreb regimen, 1 in the 6 to 17 years cohort, the other in the ≥51 years cohort); screening failure (1 subject at Day 1, in the Zagreb regimen, and in the ≥51 years cohort); and withdrawal of consent for continuing study participation (1 subject at Day 22 in the Zagreb regimen, and in the ≥51 years cohort).
Table 1. Summary of demographic characteristics of subjects enrolled in the study, by age cohort
Figure 2. Rabies virus neutralizing antibody concentrations (GMC) in the Zagreb and Essen regimens (PP set) on Days 1, 15, and 43, by age cohort. Error bars and values in parenthesis represent 95% CI.
Figure 3. Percentage of subjects with RVNA concentrations ≥0.5 IU/mL in the Zagreb and Essen regimens (PP set) on Days 15, and 43, by age cohort. Error bars and values in parenthesis represent 95% CI.
Table 2. Percentage of subjects with any and severe solicited local and systemic AEs, and other indicators of reactogenicity, from 6 hours to 7 days following any vaccination